Related Experiment Videos
Epigenetic modification is central to genome reprogramming in somatic cell nuclear transfer
Lyle Armstrong1, Majlinda Lako, Wendy Dean
1Centre for Stem Cell Biology and Developmental Genetics, University of Newcastle, International Centre for Life, Newcastle upon Tyne NE1 3BZ, UK. lyle.armstrong@ncl.ac.uk
Stem Cells (Dayton, Ohio)
|November 12, 2005
Summary
Somatic cell nuclear transfer (SCNT) can create patient-specific human embryonic stem cells (ESCs) for therapies. However, aberrant gene expression due to incomplete epigenetic reprogramming poses risks for cloned ESCs.
Area of Science:
- Stem cell biology
- Reproductive biology
- Epigenetics
Background:
- Human embryonic stem cells (ESCs) offer potential for cell replacement therapies.
- Autologous ESCs, specific to individual patients, could overcome immune rejection.
- Somatic cell nuclear transfer (SCNT) is a method for generating patient-specific ESCs.
Purpose of the Study:
- To review the mechanisms of epigenetic reprogramming during SCNT.
- To explain aberrant gene expression in SCNT-derived ESCs.
- To highlight potential risks associated with SCNT-derived ESCs.
Main Methods:
- Review of current literature on SCNT and ESC derivation.
- Analysis of epigenetic modifications (DNA methylation, histone modification) in SCNT.
- Examination of gene expression patterns in cloned embryos and ESCs.
Main Results:
- SCNT requires resetting the somatic cell's epigenetic program to an embryonic state.
- Incomplete reprogramming leads to aberrant gene expression in cloned embryos and ESCs.
- Aberrant epigenetic modifications are a key factor in SCNT failures.
Conclusions:
- SCNT offers a pathway to autologous ESCs but faces challenges in complete epigenetic reprogramming.
- Aberrant gene expression in SCNT-derived ESCs presents potential dangers for therapeutic applications.
- Further research into epigenetic mechanisms is crucial for safe and effective SCNT-based therapies.